Publications by authors named "Marie Eichler"
The maximum response and 10-year survival rate for metastatic melanoma patients treated with standardised chemotherapy is still less than 15% and 10%, respectively. In contrast, oncogene targeting was found a promising tool for killing of BRAF mutated melanoma cells. Nevertheless, despite improved response and survival rates, resistance acquisition remains an ongoing problem.
View Article and Find Full Text PDFArticle Synopsis
- Aggressive cancers like neuroblastoma and glioblastoma are challenging to treat and often have poor outcomes, highlighting the need for new chemotherapy options.
- A novel device combining 2D and 3D culture systems with real-time impedance measurement was developed to assess drug efficacy more effectively.
- Tests showed that while common chemotherapies like doxorubicin, etoposide, and vincristine induced cell death in neuroblastoma, etoposide was ineffective against glioblastoma, underscoring the importance of understanding cancer-specific responses for drug development.
For selective killing of tumor cells, there are many novel and promising therapeutic approaches like immunotoxins. However, on the long way to clinical application, especially in vitro approved biologicals often fail due to loss of target sensitivity and efficacy in vivo. This is mostly explained with degradation or penetration disability in vivo.
View Article and Find Full Text PDF